619 Durvalumab plus carboplatin/paclitaxel followed by durvalumab ± olaparib as a first-line treatment for newly diagnosed advanced or recurrent endometrial cancer: results from the phase III DUO-E/GOG-3041/ENGOT-EN10 TrialShannon N Westin,Kathleen N Moore,Hye Sook Chon,Jung-Yun Lee, Jessica Thomes Pepin, Michael Sundborg, Joseph De La Garza,Shin Nishio, Ke Wang,Kristi Mcintyre,Todd D Tillmanns, Fernando Contreras Mejia,Andreia Cristina De Melo, Dagmara Klasa-Mazurkewicz,Christos Papadimitriou,Marta Gil-Martin, Birute Brasiuniene, Conor Donnelly,Xiaochun Liu,Els Van NieuwenhuysenOral Sessions（2024）引用 0|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
